Hsu Yueh-Han, Yu Hui-Yi, Chen Hsuan-Ju, Li Tsai-Chung, Hsu Chih-Cheng, Kao Chia-Hung
Department of Health Services Administration, China Medical University, Taichung, Taiwan.
Division of Nephrology, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan.
PLoS One. 2016 Jun 10;11(6):e0156863. doi: 10.1371/journal.pone.0156863. eCollection 2016.
PURPOSE: The changes of the risk of peripheral arterial disease (PAD) in patients with end-stage renal disease after parathyroidectomy are scant. METHODS: We used a nationwide health insurance claims database to select all dialysis-dependent patients with end-stage renal disease aged 18 years and older for the study population in 2000 to 2006. Of the patients with end-stage renal disease, we selected 947 patients who had undergone parathyroidectomy as the parathyroidectomy group and frequency matched 3746 patients with end-stage renal disease by sex, age, years since the disease diagnosis, and the year of index date as the non-parathyroidectomy group. We used a multivariate Cox proportional hazards regression analysis with the use of a robust sandwich covariance matrix estimate, accounting for the intra-cluster dependence of hospitals or clinics, to measure the risk of peripheral arterial disease for the parathyroidectomy group compared with the non-parathyroidectomy group after adjusting for sex, age, premium-based income, urbanization, and comorbidity. RESULTS: The mean post-op follow-up periods were 5.08 and 4.52 years for the parathyroidectomy and non-parathyroidectomy groups, respectively; the incidence density rate of PAD in the PTX group was 12.26 per 1000 person-years, significantly lower than the data in the non-PTX group (24.09 per 1000 person-years, adjusted HR = 0.66, 95% CI = 0.46-0.94). CONCLUSION: Parathyroidectomy is associated with reduced risk of peripheral arterial disease in patients with end-stage renal disease complicated with severe secondary hyperparathyroidism.
Medicine (Baltimore). 2015-6
Nephrology (Carlton). 2016-2
J Am Soc Nephrol. 2001-6
Curr Vasc Pharmacol. 2024
Diabetes Metab Syndr Obes. 2023-10-26
Front Endocrinol (Lausanne). 2023
Int Urol Nephrol. 2018-7
Rev Endocr Metab Disord. 2017-3
Medicine (Baltimore). 2015-6
Clin J Am Soc Nephrol. 2015-1-7
Semin Nephrol. 2014-11
Cochrane Database Syst Rev. 2014
J Am Soc Nephrol. 2015-2